

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/063292 A1

(51) International Patent Classification:

C12P 21/02 (2006.01) *C12N 5/16* (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:

PCT/US2005/044735

(22) International Filing Date:

8 December 2005 (08.12.2005)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/634,355 8 December 2004 (08.12.2004) US

(71) Applicant (for all designated States except US): **ICOS CORPORATION** [US/US]; 22021 20th Avenue S.E., Bothell, Washington 98021 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **ALLISON, Daniel, S.** [US/US]; 3612 Ne 189th Place, Seattle, Washington 98155 (US).

(74) Agents: **NEVILLE, Katherine, L.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Sears Tower, Chicago, Illinois 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: RECOMBINANT METHOD FOR MAKING MULTIMERIC PROTEINS

(57) Abstract: The present invention relates to methods for making multimeric proteins comprising fusion of two or more cells expressing a single subunit of the multimeric protein to generate a single hybrid cell expressing the fully assembled multimeric protein.



WO 2006/063292 A1

RECOMBINANT METHOD FOR MAKING MULTIMERIC PROTEINS

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/634,355, filed December 8, 2004, incorporated herein by reference.

FIELD OF THE INVENTION

[0002] The present invention relates to a method for making a multimeric protein, wherein the multimeric protein is made by fusing a cell expressing one subunit of the multimeric protein with at least one other cell expressing another subunit of the multimeric protein.

BACKGROUND OF THE INVENTION

[0003] Recombinant proteins are often produced using stably transfected mammalian cell lines. However, random integration of plasmids within chromosomal DNA results in highly variable protein production levels between different transfectants. As a consequence, a large number of transfectants must be screened to identify those with even a moderate level of protein expression. Furthermore, isolation of highly productive cell lines usually requires amplification of the gene encoding the protein of interest. This is typically done either by linking the gene to be expressed directly to a dihydrofolate reductase gene (*dhfr*) or by co-transfecting a *dhfr*-negative CHO cell line with both the gene of interest and the *dhfr* gene, followed by stepwise selection in increasing levels of methotrexate [Kaufman et al., *Meth. Enzymol.* (1990) 185:537-566]. Constructing highly productive cell lines using this approach is thus a laborious and time-consuming process. In addition, cell lines carrying amplified chromosomal regions are often unstable and lose high level expression after growth in the absence of selective pressure [Weidle et al., *Gene* (1988) 66:193-203; Fann et al., *Biotechnol. Bioeng.* (2000) 69:204-212].

[0004] Reducing the need for gene amplification would require a many-fold increase in the rate of transcription of each copy of a transfected recombinant

gene. Transcription rates of recombinant genes in transfected cell lines are determined both by trans-acting factors specific to the cell line used for expression (e.g., transcription factors), and by cis-acting elements. Cis-acting elements include the promoter and enhancer present in the expression vector, as well as other less-well understood elements present in chromosomal sequences near the site of plasmid integration and which are responsible for position effects [Dillon et al., *Trends Genet.* (1993) 9:134-137; Hendrich et al., *Hum. Mol. Genet.* (1995) 4:1765-1777; Hennig, W. *Chromosoma* (1999) 108:1-9].

[0005] In many eukaryotes there are non-coding polynucleotide sequences that enhance gene transcription, for example enhancers, promoters, and locus control regions (LCR), which help regulate tissue specific gene expression [Needham et al., *Protein Expression and Purification* (1995) 6:124-131]. Recent studies have attempted to make expression vectors which produce increased gene expression by including elements such as a transcriptional enhancer [Khoury et al., *Cell* (1983), 33:313-314; Blackwood et al., *Science* (1998), 281:60-63], insulator element [Gerasimova et al., *Annu. Rev. Genet.* (2001), 35:193-208; West et al., *Genes Dev.* (2002), 16:271-288], scaffold/matrix attachment region [Bode et al., *Crit. Rev. Eukaryot. Gene Expr.* (2000), 10:73-90], or transcription termination element [Proudfoot et al., *Nature* (1986), 322:562-565]. Expression vectors have recently been described that provide increased expression in transfected CHO cells, but depend upon a non-promoter sequence such as an ubiquitous chromatin opening element (UCOE) [Benton et al., *Cytotechnology* (2002) 38:43-46; International Patent Publication WO 00/05393] or a chicken lysozyme matrix-attachment region (MAR) [Zahn-Zabal et al., *J. Biotechnol.* (2001) 87:29-42].

[0006] Unlike locus control regions (LCR) of a gene, ubiquitous chromatin opening elements are DNA sequences which can enhance gene expression in multiple tissue types (International Patent Publication WO 00/05393). Recent studies have shown that expression of the erythropoietin gene in CHO cells is enhanced when under the control of a UCOE compared to control by a CMV promoter only [WO 00/05393]. One drawback to using UCOEs to

facilitate increased gene transcription, however, is their large size, which can be anywhere from 7kb to 60 kb.

[0007] Matrix-attachment regions are DNA sequences that bind nuclear matrices with high affinity and are thought to define boundaries of chromatin domains. MAR elements have been shown to interact with gene enhancers to increase chromatin accessibility and demonstrate enhanced expression of heterologous genes in cultured cell lines [Zahn-Zabal et al., *supra*]. Thus, MAR elements provide a method for increasing gene expression of heterologous DNA in culture without use of amplification agents.

[0008] Recombinant production of multisubunit proteins has proven difficult due to the large amount of DNA and number of plasmids that must be transfected into a single cell to get expression of a functional multisubunit protein. Often the subunits must be expressed in specific ratios to facilitate the optimal assembly of the subunits and subsequent expression of the large protein. Because effective expression of plasmid derived DNA is often limited by insertion site and promoter activity, the protein ratio required by multisubunit proteins is difficult to regulate due to insertion site effects of expression of each gene and control of each subunit gene by various control elements.

[0009] Antibodies are multisubunit proteins composed, at their simplest form, of two identical heavy chain and two identical light chain polypeptides joined by disulfide bonds. Antibodies are categorized by class (IgM, IgG, IgD, IgE and IgA) based on the heavy chain gene (C_H) they express (μ , γ , δ , ϵ , α). Antibodies may comprise either one of the two light chain genes (C_L), κ or λ . Each heavy chain and light chain polypeptide is encoded by a distinct gene, and the products are translated as separate proteins and assembled in the endoplasmic reticulum of the cell to create the functional multisubunit protein. Recombinant antibody production has been practiced for several years, but initially involved transfection of bacteria or yeast with a single gene encoding either a heavy chain or light chain subunit, and subsequently recovering each protein from its respective cell culture and reassembling the antibody subunits outside the cells. [Cabilly et al., *Proc. Natl. Acad. Sci. U.S.A.* (1984) 81:3273-

7; and U.S. Patent 4,816,567; Wood et al., *J. Immunol.* (1990)145:3011-16; Simmons et al., *J. Immunol. Meth.* (2002) 263:133-47].

[0010] More recent methods of making recombinant antibodies involve co-transfection of separate vectors respectively expressing a single heavy chain and a light chain into the same cell. This has reportedly been done in mammalian cells [Bender et al., *Hum. Antibodies Hybridomas* (1993) 4:74-9; Chin et al., *Biologicals* (2003) 31:45-53; Fan et al., *Biol. Chem.* (2002) 383:1817-20; Nagahira et al., *Immunol. Lett.* (1998) 64:139-44] and in insect cells [Hasemann et al., *Proc. Natl. Acad. Sci. U.S.A.* (1990) 87:3942-6; Guttieri et al., *Hybrid Hybridomas* (2003) 22:135-45]. While these techniques potentially allow for assembly of the antibody in the cellular environment, they are subject to difficulties in maintaining expression of two heterologous proteins in an appropriate ratio. For example, in mammalian cells, an antibody heavy chain is often not secreted in the absence of light chain [Struzenberger et al., *J. Biotechnol.* (1999) 69:215-226].

[0011] Monoclonal antibodies are a key therapeutic product in the treatment of numerous conditions and diseases that affect the human population, including autoimmune diseases and cancer. Recombinant monoclonal antibodies are typically made using a co-transfection method as stated above. However, other methods have been described, such as fusion of two monoclonal antibody-producing hybridomas to produce chimeric or bispecific antibodies having a multitude of specificities [Auriol et al., *J. Immunol. Meth.* (1994) 169:123-33]. Unfortunately, the variability and specificity of the antibodies produced by this technique are too broad when large amounts of single antibody are desired.

[0012] Some recent studies have attempted to produce monoclonal antibodies by fusion of two cells, each expressing a different subunit of a multisubunit protein. For example, Norerhaug et al. [*Eur. J. Biochem.* (2002) 269:3205-10], have attempted to express the secreted isoform of IgA (sIgA), composed of an antibody heavy chain, a light chain, a joining chain (J) and a secretory component (SC). In a multi-step fusion process, a single cell transfected with a plasmid encoding both an antibody heavy chain and a light chain was fused to a cell expressing the antibody J chain, with subsequent

fusion of the first fusion product (heavy chain, light chain, J chain in one cell) to a cell expressing the antibody secretory component. While the slgA molecule is described as having been successfully assembled, this study did not attempt to express the antibody heavy chain gene separately from the light chain gene, which is the primary difficulty in recombinant antibody formation [Struzenberger et al., *supra*].

[0013] Ryll et al [see U.S. Patent Publication No. 20040053363] reports an attempted fusion of two cells separately expressing the heavy and light chain genes with mixed success. This protocol requires addition of amplification agents that can be toxic to the cell, and may not provide an appropriate ratio of the heavy chain to light chain required for significant antibody production in these cells, thereby leading to low multimeric protein recovery. U.S. Patent Nos. 6,677,138, 6,420,140, 6,207,138, and 5,916,771 describe a method of making a protein using cell fusion techniques, but this protocol also requires addition of amplification agents, and no actual product is demonstrated from this method.

[0014] Thus, there remains a need in the art for rapid, large scale production of therapeutically relevant multimeric or multisubunit proteins, such as monoclonal antibodies, wherein the production protocol provides a non-toxic method for growing large numbers of cells and wherein the cells produce each subunit of the multisubunit protein in appropriate ratios.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The present invention provides novel methods for making a recombinant multimeric protein, wherein the production of the multimeric protein in mammalian cells circumvents the need for addition of toxic agents to the cell culture in order to promote gene amplification and increased protein expression.

[0016] The present invention contemplates a method for making a multimeric protein comprising the steps of: transfecting a first host cell with a first plasmid comprising a first polynucleotide encoding a first polypeptide of the multimeric protein, wherein the plasmid is not amplified using an

amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the first polypeptide; transfecting a second host cell with a second plasmid comprising a second polynucleotide encoding a second polypeptide of the multimeric protein, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the second polypeptide; fusing the first host cell with the second host cell to make a cell hybrid, wherein the cell hybrid expresses the first and second polypeptides, and; culturing the cell hybrid in culture media under conditions that permit the expression and association of the polypeptides to form the multimeric protein.

[0017] In one embodiment, the method is performed without first selecting for clones expressing the first and second polypeptides prior to the step of fusing the first host cell expressing the first polypeptide and the second host cell expressing the second polypeptide.

[0018] In another embodiment, the method optionally comprises one or both of the steps of: selecting a first host cell expressing the first polypeptide by culturing under conditions that permit the expression prior to the fusing step; selecting a second host cell expressing the second polypeptide by culturing under conditions that permit the expression prior to the fusing step.

[0019] In another aspect, the method further comprises as many additional transfecting steps as needed to produce a recombinant multisubunit protein having more than two subunits. It is contemplated that the method of the invention optionally comprises one additional transfection step for each additional polypeptide component of the multimeric protein. For example, in one embodiment, multimeric proteins comprising more than two subunits (for example, trimers) are generated using the fusion process described above, wherein polynucleotides encoding the additional protein subunits are inserted into a plasmid, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the encoded polypeptide. This step may be repeated for each subunit of the multimeric protein. The method further comprises the steps of inserting the plasmid into

another host cell; fusing the host cell with the host cells fused previously to make an additional cell hybrid, and culturing the cell hybrid in culture media under conditions that permit the expression and association of the polypeptides to form the multimeric protein. The method optionally comprises selecting host cells expressing the additional polypeptide prior to the fusing step. Exemplary trimeric proteins include antibodies of the IgM and IgA subclass, which are composed of a heavy chain, a light chain, and a J chain.

[0020] It is contemplated that each plasmid in the transfection step may contain a different selectable marker, including, but not limited to, NeoR (conferring resistance to geneticin), DHFR (allowing cells that lack a functional DHFR gene, such as CHO DG44, to grow in the absence of hypoxanthine and thymidine, and conferring resistance to methotrexate after gene amplification), HisD (conferring resistance to histidinol), PuromycinR (conferring resistance to puromycin), ZeocinR (conferring resistance to zeocin), and GPT (conferring resistance to xanthine-guanine phosphoribosyl-transferase (XGPRT)).

[0021] By “multimeric” or “multisubunit” is meant a protein comprised of two or more protein subunits. “Multimeric” proteins include heterodimeric or hetero-oligomeric proteins.

[0022] By “transformed” or “transfected” is meant that the host cell is modified to contain an exogenous polynucleotide, which can be chromosomally integrated or maintained in the cell as an episomal element. It is contemplated that in the method of the invention the host cell is transfected in a “transfection step.” The method may comprise multiple transfection steps.

[0023] By the terms “a first polypeptide” or “a first polynucleotide” is meant, respectively, the amino acid sequence of, or the nucleotide sequence encoding a single subunit of a multimeric protein that may be expressed by a host cell.

[0024] By the terms “a second polypeptide” or “a second polynucleotide” is meant, respectively, the amino acid sequence of, and the nucleotide sequence encoding a single subunit of a multimeric protein that is different

from, respectively, the first polypeptide or the first polynucleotide, and which is also expressed by a host cell.

[0025] By the term "first host cell" is meant the host cell used to express the subunit encoded by the first polynucleotide, while the term "second host cell" means the host cell used to express the subunit encoded by the second polynucleotide.

[0026] It is contemplated that when the multisubunit protein comprises more than a "first polypeptide" and a "second polypeptide", the additional subunits contemplated will be termed "third polypeptide or third polynucleotide", and may increase sequentially with each additional subunit. The same terminology criteria may be followed in denominating the host cell and plasmids utilized.

[0027] By the term "fusing" or "fusion" of two or more cells is meant a method in which two or more cells are combined to form a single hybrid cell which contains all or part of at least the nucleic acid content of each individual cell. Fusion may be accomplished by any method of combining cells under appropriate conditions well known in the art [See, for example, Harlow & Lane (1988) in *Antibodies*, Cold Spring Harbor Press, New York]. Known methods for fusing cells include, for example, use of polyethylene glycol (PEG) or Sendai virus. Cells may also be fused using electrofusion [Stoicheva et al., *J. Membr. Biol.* (1994) 141(2):177-82].

[0028] By the term "fusant" or "hybrid cell" is meant a cell formed by combining two or more cells, e.g., by fusion. In the method of the invention, fusants are formed from the fusion of at least two transformed or transfected cells each expressing a different single subunit of a multimeric protein.

[0029] By the term "regulatory DNA" is meant DNA sequences, often called cis-acting elements, that are present in chromosomal sequences and that help regulate gene expression. Regulatory DNA includes, but is not limited to, promoters, enhancers, transcriptional enhancers, insulator elements, scaffold/matrix attachment regions, transcription termination elements, ubiquitous chromatin opening elements (UCOE), or other elements present in chromosomal sequences responsible for position effects.

[0030] To determine if the cultured cell hybrid permits the expression and association of the multimeric protein, methods for screening both polypeptides and polynucleotides may be performed. The protocol for screening for the protein of interest depends upon the nature of the polypeptide encoded by the inserted polynucleotide and, in some instances, the nature of the host cell. For example, where the recombinant cell contains a polynucleotide that, when expressed, does not produce a secreted product, selection or screening for the presence of cells having the introduced polynucleotide can be accomplished by Northern or Southern blot using a portion of the exogenous polynucleotide sequence as a probe, or by polymerase chain reaction (PCR) using sequences derived from the exogenous polynucleotide sequence as probe. Screening for the expressed, non-secreted polypeptide may be performed using intracellular fluorescent staining by fluorescence activated cell sorting (FACS), through immunoprecipitation methods, or other methods known in the art. If the introduced polynucleotide encodes a secreted polypeptide, the polypeptide may be detected using immunoprecipitation of the polypeptide from the media, or through other detection methods known in the art, such as enzyme-linked immunosorbant assay (ELISA) or FACS.

[0031] After fusion of the cells is complete, the recombinant cells containing all the desired polynucleotide sequences can also be identified by detecting expression of a functional multimeric product using, for example, immuno-detection of the product (ELISA, FACS). Alternatively, the expression product can be detected using a bioassay to test for a particular effector function or phenotype conferred by expression of the exogenous sequence(s).

[0032] A regulatory DNA contemplated for use in the methods of the invention can be joined to a polynucleotide encoding a monomer of a multimeric protein by any of a variety of other linking nucleotide sequences through well-established recombinant DNA techniques [see Sambrook et al. (2d Ed.; 1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY]. Useful nucleotide sequences for joining to polypeptides include an assortment of vectors, e.g., plasmids, cosmids, lambda phage derivatives, phagemids, and the like, that are well known in the art. The invention also provides a vector including a polynucleotide of the

invention and a host cell containing the polynucleotide. In general, the vector contains an origin of replication functional in at least one organism, convenient restriction endonuclease sites, and a selectable marker for the host cell. Useful vectors include, for example, expression vectors, replication vectors, probe generation vectors, sequencing vectors, and retroviral vectors. The host cell can be a eukaryotic cell and can be a unicellular organism or part of a multicellular organism. Large numbers of suitable vectors and promoters are known to those of skill in the art and are commercially available for generating the recombinant constructs of the present invention.

[0033] A variety of expression vector/host systems may be utilized to contain and express a polynucleotide contemplated by the invention. These include, but are not limited to, yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transfected with virus expression vectors (e.g., Cauliflower Mosaic Virus (CaMV); Tobacco Mosaic Virus (TMV)) or transformed with bacterial expression vectors (e.g., Ti or pBR322 plasmid); or animal cell systems. Mammalian cells that are useful in recombinant protein production include, but are not limited to, VERO cells, HeLa cells, Chinese hamster ovary (CHO) cells, COS cells (such as COS-7), WI38, BHK, HepG2, 3T3, RIN, MDCK, A549, PC12, K562 and HEK 293 cells.

[0034] It is contemplated that the methods of the invention utilize a plasmid comprising a transcription regulatory DNA. It is contemplated that the regulatory DNA may be, but is not limited to, a CHEF1 transcription regulatory DNA, a MAR element, or a ubiquitous chromatin opening element (UCOE).

[0035] For example, to make a plasmid containing a transcription regulatory DNA, the polynucleotide encoding the Chinese hamster EF1- α regulatory sequence, termed the CHEF1 transcription regulatory DNA (SEQ ID NO: 1 or SEQ ID NO: 2) is inserted into a plasmid for use in either yeast or mammalian expression systems. It is preferable that the CHEF1 regulatory DNA is used in a mammalian expression vector system, and more preferably CHEF1 is used in CHO cells. In another embodiment, the expression vector comprises a UCOE or MAR element to promote increased gene expression. In various embodiments, the method of the invention provides that the first or

second plasmid is pNEF5, pDEF14, pDEF2, pDEF10 (described in US Patent No. 5,888,809), pNEF38, pDEF38 [described in Running Deer et al. (*Biotechnol. Prog.* (2004) 20:880-889] or pHLEF38 (described herein).

[0036] The first host cell and the second host cell of the invention can be cells from the same species. For example, the first host cell and the second host cell can be the same type of cell from the same species. The first host cell and the second host cell can also be different cells from the same species. The first host cell and second host cell may be from different species, for example as described in Dessain et al. [*J. Immunol. Meth.* (2004) 291:109-22], which describes fusion of a mouse cell line and human B cells to generate antibody producing cells, or Mariani et al. [*J. Virol.* (2001) 75:3141-51], which describes fusion of human or murine cells with cells from various species. The first host cell and the second host cell can be mammalian cells. The mammalian cells can be CHO cells.

[0037] Multimeric proteins in nature may be categorized as homo-oligomeric proteins, large globular proteins, which comprise multiple subunits of the same protein product. These globular proteins include such molecules as collagen, myosin, the resistin family of hormones, and others well known in the art. These types of multimeric proteins are generally expressed from single plasmids and do not require co-transfection of multiple plasmids encoding each subunit. However, many multisubunit proteins are transcribed from different genes and assembled within the cell machinery. Multimeric proteins comprising subunits transcribed from different genes, for example heterodimeric proteins or hetero-oligomeric proteins, contemplated for manufacture through the methods of the invention include, but are not limited to, antibodies, integrins, soluble and membrane-bound forms of MHC (major histocompatibility complex) class I or class II molecules, T cell receptors, the gamma-secretase protease complex, bone morphogenic protein BMP2/BMP7 heterodimeric osteogenic protein, ICE (interleukin-1 converting protein), receptors of the nucleus (e.g., retinoid receptors), heterodimeric cell surface receptors (soluble and membrane forms), tumor necrosis factor (TNF) receptor, and other multimeric proteins in the art.

[0038] A multimeric protein made according to the invention can be an antibody product. Antibody products include, but are not limited to, monoclonal antibodies, humanized antibodies, human antibodies, chimeric antibodies, bifunctional/bispecific antibodies, complementary determining region (CDR)-grafted antibodies, Fv fragments, Fab fragments, Fab' fragments, and F(ab')₂ fragments.

[0039] Antibody products also include CDR sequences or modified CDR sequences, which specifically recognize an antigen of interest. Such antibody products may be chimeric or humanized antibodies, i.e., antibodies that have fully human or largely human antibody structure so as to minimize antigenicity of the antibody itself and otherwise interact with a human immune system in a manner that mimics a true human antibody. Such antibody products may also be human antibodies, which can be produced and identified according to methods described in the art, e.g., in international patent publication WO93/11236, which is incorporated herein by reference in its entirety.

[0040] The method of the invention can use DNA encoding an antibody heavy chain or a light chain, or variants or fragments thereof, isolated from a monoclonal or polyclonal antibody which may be produced using techniques common in the art. A monoclonal antibody specific for an antigen of interest may be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not limited to the hybridoma technique originally described by Köhler et al., *Nature* (1975) 256: 495-497), the more recent human B-cell hybridoma technique [Kosbor et al., *Immunol. Today* (1983) 4: 72] and the EBV-hybridoma technique [Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R Liss, Inc., pp. 77-96 (1985), all specifically incorporated herein by reference].

[0041] When the hybridoma technique is employed to make a monoclonal antibody, myeloma cell lines may be used. Such cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and exhibit enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of only the desired fused cells (hybridomas). For example, where the

immunized animal is a mouse, one can use hybridomas P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4 1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7 and S194/5XX0 Bul; for rats, one can use hybridomas R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210; U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6. Any of these may be useful in connection with cell fusions as described herein.

[0042] The fusant DNAs encoding a monoclonal antibody may be used to produce modified forms of the antibody, such as those that utilize variants or fragment of the antibody sequence, including humanized antibodies, human antibodies, chimeric antibodies, bifunctional/bispecific antibodies, complementary determining region (CDR)-grafted antibodies, Fv fragments, Fab fragments, Fab' fragments, and F(ab')₂ fragments. DNAs collectively encoding the modified forms of the antibody may then be used to practice the method of the invention, wherein a fully assembled modified antibody is made by fusion of two or more host cells containing single different subunits of the modified antibody.

[0043] For example, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used [Morrison et al., *Proc. Natl. Acad. Sci. U.S.A.* (1984) 81: 6851-6855; Neuberger et al., *Nature* (1984) 312: 604-608; Takeda et al., *Nature* (1985) 314: 452-454] to generate a chimeric antibody.

[0044] Antibody fragments that contain the idiotype of the molecule may be generated by known techniques. For example, such fragments include, but are not limited to, the F(ab')₂ fragment which may be produced by pepsin digestion of the antibody molecule; the Fab' fragments which may be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the two Fab' fragments which may be generated by treating the antibody molecule with papain and a reducing agent.

[0045] Non-human antibodies may be humanized by any methods known in the art. A preferred chimeric or humanized antibody has a human constant region, while the variable region, or at least a CDR, of the antibody is derived

from a non-human species. Methods for humanizing non-human antibodies are well known in the art [see U.S. Patent Nos. 5,585,089 and 5,693,762]. Generally, a humanized antibody has one or more amino acid residues introduced into its framework region from a source which is non-human. Humanization can be performed, for example, using methods described in Jones et al. [*Nature* (1986) 321:522-525], Riechmann et al., [*Nature* (1988) 332:323-327] and Verhoeyen et al. [*Science* (1988) 239:1534-1536], by substituting at least a portion of one or more rodent complementarity-determining regions (CDRs) for the corresponding regions of a human antibody. Numerous techniques for preparing engineered antibodies are described, e.g., in Owens and Young, [*J. Immunol. Meth.* (1994) 168:149-165]. Further changes can then be introduced into the antibody framework to modulate affinity or immunogenicity.

[0046] Polypeptides comprising CDRs are generated using techniques known in the art. Complementarity determining regions are characterized by six polypeptide loops, three loops for each of the heavy or light chain variable regions. The amino acid position in a CDR is defined by Kabat et al., "Sequences of Proteins of Immunological Interest," U.S. Department of Health and Human Services, (1983), which is incorporated herein by reference. For example, hypervariable regions of human antibodies are roughly defined to be found at residues 28 to 35, from 49-59 and from residues 92-103 of the heavy and light chain variable regions [Janeway and Travers, *Immunobiology*, 2nd Edition, Garland Publishing, New York, (1996)]. The murine CDRs also are found at approximately these amino acid residues. It is understood in the art that CDRs may be found within several amino acids of the approximate residues set forth above. An immunoglobulin variable region also consists of four "framework" regions surrounding the CDRs (FR1-4). The sequences of the framework regions of different light or heavy chains are highly conserved within a species, and are also conserved between human and murine sequences.

[0047] Polypeptides comprising one, two, and/or three CDRs of a heavy chain variable region or a light chain variable region of a monoclonal antibody are generated. For example, based on an antigen-specific monoclonal

antibody, polypeptide compositions comprising isolated CDRs are generated. Polypeptides comprising one, two, three, four, five and/or six complementarity determining regions of a monoclonal antibody secreted by a hybridoma are also contemplated. Using the conserved framework sequences surrounding the CDRs, PCR primers complementary to these consensus sequences are generated to amplify the antigen-specific CDR sequence located between the primer regions. Techniques for cloning and expressing nucleotide and polypeptide sequences are well-established in the art [see e.g. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edition, Cold Spring Harbor, New York (1989)]. The amplified CDR sequences are ligated into an appropriate plasmid. The plasmid comprising one, two, three, four, five and/or six cloned CDRs optionally contains additional polypeptide encoding regions linked to the CDR.

[0048] The DNA encoding any of the antibody subunits of the above-described modified antibodies are then transfected into separate host cells which are then fused to generate a fusant expressing a fully assembled modified antibody.

[0049] In one simple embodiment, it is contemplated that the first polynucleotide transfected into the first host cell encodes an antibody heavy chain polypeptide or any variant or fragment thereof, while the second polynucleotide transfected into the second host cell encodes an antibody light chain polypeptide or any variant or fragment thereof.

[0050] In another embodiment, the invention contemplates a method for making an antibody comprising the steps of: a) transfecting a first host cell with a first plasmid comprising a first polynucleotide encoding a heavy chain polypeptide of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the heavy chain polypeptide; b) transfecting a second host cell with a second plasmid comprising a second polynucleotide encoding a light chain polypeptide of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the

light chain polypeptide; c) fusing the host cells to make a cell hybrid, wherein the cell hybrid expresses the heavy chain polypeptide and the light chain polypeptide; and, d) culturing the cell hybrid in culture media under conditions that permit the expression and association of the heavy chain and the light chain to form the antibody.

[0051] In a related embodiment, the method of making an antibody further comprises, before step (c) the step of: (b') transfecting a third host cell with a third plasmid comprising a third polynucleotide encoding a J chain of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the light chain.

[0052] It is further contemplated in the method for making an antibody that the fusing step (b) comprises: (i) fusing the transfected host cells obtained from any two of the transfecting steps (a), (b) and (b') to form an intermediate fusant and (ii) fusing the intermediate fusant with the transfected host cells obtained from the remaining transfecting step (a), (b), or (b') not fused in (i) to obtain the cell hybrid.

[0053] In another embodiment, it is contemplated that the antibody is a Fab fragment, and the heavy chain polypeptide and the light chain polypeptide are fragments capable of permitting expression and association of the Fab fragment.

EXAMPLES

[0054] The following examples are provided to illustrate the invention, but are not intended to limit the scope thereof. Example 1 describes the generation of plasmids comprising the CHEF1 regulatory DNA sequence. Example 2 describes pre-selection fusion of CHO cells each producing a single different antibody heavy chain or light chain subunit. Example 3 describes post-selection fusion of CHO cells each producing a single different antibody heavy chain or light chain subunit.

EXAMPLE 1 GENERATION OF CHEF1 DRIVEN PLASMIDS

[0055] To obtain high level expression of heterologous genes without using toxic amplification agents, the present invention contemplates use of the Chinese hamster elongation factor-1 α (EF-1 α) gene 5' and 3' flanking sequences. These sequences are described in US Patent No. 5,888,809, which is hereby incorporated by reference.

[0056] Cloning and sequencing the Chinese hamster EF-1 α gene. The Chinese Hamster EF-1 α gene was cloned from a CHO-K1 genomic library in Lambda FIX II obtained from Stratagene (La Jolla, CA) as set out in US Patent No. 5,888,809 and Running Deer et al. [*Biotechnol. Prog.* (2004) 20:880-889]. The 18,794 bp of sequence containing the Chinese hamster EF-1 α gene and flanking regions has been deposited in Genbank® (Accession number AY188393).

[0057] Expression plasmids. The approximately 3.6 kb sequence of the CHEF1 regulatory DNA, including at least the CHEF1 promoter and the 5' intron, is set out in SEQ ID NO: 1. An approximately 4.1 kb 5' flanking region, recently shown to give increased gene expression [Running Deer et al., (*supra*)], is set out in SEQ ID NO: 2. The CHEF1 plasmid pDEF14 [Running Deer et al., (*supra*)] was constructed to include the following segments of DNA: an 11.7 kb DNA fragment from the 5' flanking region of the CHEF1 gene; 27 bp of synthetic sequence containing HindIII and XbaI sites for insertion of genes to be expressed; a 0.5 kb fragment carrying the phage f1 origin of replication; a 1.8 kb fragment from pSV2-dhfr, which carries a murine dihydrofolate reductase (*dhfr*) cDNA under the control of promoter/poly(A) addition sequences from the SV40 genome; a 4.2 kb MscI/Sall fragment from the 3' flanking region of the CHEF1 gene (SEQ ID NO: 3); a 2.2 kb fragment from pBR322 carrying a bacterial origin of replication and the ampicillin resistance gene. To facilitate joining of CHEF1 5' flanking regions to coding sequences to be expressed, a HindIII site was introduced 15 bp downstream of the acceptor splice site of intron 1 in the CHEF1 gene. The CHEF1 plasmid pNEF5 [Running Deer et al., *supra*] is

identical to pDEF14 except that in pNEF5, the *dhfr* expression cassette is replaced with a 1.5 kb fragment carrying the neomycin resistance gene (neoR) under the control of SV40 promoter/poly(A) addition sequences. For expression of genes in pDEF14, or pNEF5, a three-way ligation is performed using (1) a HindIII/XbaI fragment carrying the gene of interest, (2) a 737 bp NotI/HindIII fragment from pDEF14, and (3) a ~19 kb NotI/XbaI vector fragment from the respective vector pDEF14, or pNEF5 .

[0058] It is contemplated that the size of the 5' flanking region may be a 4.1 kb fragment from the 5' flanking region of the CHEF1 gene, including a 6 bp HindIII site at the end of the sequence (SEQ ID NO: 2). For example, CHEF1 vectors pDEF38 and pNEF38 [described in Running Deer et al. (*supra*)], are identical to pDEF14 and pNEF5, respectively, except that pDEF38 and pNEF38 contain only 4.1 kb of CHEF1 5' flanking sequence, a more extensive polylinker region, and a 623 base pair PCR-generated XbaI/Sall fragment from the CHEF1 3' flanking sequence that carries the CHEF1 poly(A) addition sequence, and is positioned on the 3' side of the polylinker used for insertion of genes to be expressed.

[0059] Also contemplated for use in accordance with the invention is CHEF1 vector pHLEF38. Plasmid pHLEF38 is identical to pNEF38 except in pHLEF38, the neo gene is replaced with the histidinol gene (HisD) as the selectable marker. pHLEF38 was constructed via several intermediate plasmids. The first step was to ligate a synthetic linker (5'-AAGCTTCAAGTTATGCTCTAGAATCCGGTACCTCGAGAAAATGCATGGCAGTCGAC -3') (SEQ ID NO: 4) which contained HindIII, XbaI, XhoI, NsiI and Sall sites (in that order) into pSL1190 (Pharmacia) cut with HindIII and Sall, creating pSL1190mod. A 4.1 kb NsiI-Sall fragment from pSK/EF1.7 [Running Deer et al., *supra*] containing the CHEF1 3' flanking sequence was inserted into the NsiI-Sall sites of pSL1190mod, creating plasmid pSL1190mod/EF13prime.

[0060] Next, a 7.29 kb XbaI-XhoI vector fragment from pSL1190mod/EF13prime was ligated to a 638 bp XbaI-BamHI fragment from pDEF38 [Running Deer et al., *supra*] containing the CHEF1 polyA, and a 3.86 kb BamHI-Sall fragment from pHLEF1 (see below) containing the HisD gene,

creating pSL1190mod/HLEF38. This ligation destroys both the internal XhoI and Sall sites, leaving a unique Sall site at the 3' end of the CHEF1 3' flank intact in this vector. The 4.2 kb 3' flanking sequence has also been shown to be important for gene expression [Running Deer et al., *supra*]

[0061] Finally, a 8.65 kb XbaI-Sall fragment from pSL1190mod/HLEF38, containing the CHEF1 polyA, His-D marker cassette and CHEF1 3' flank, was ligated to a 6.3 kb XbaI-Sall vector fragment from pDEF38 to create pHLEF38.

[0062] To create pHLEF1, a 3kb SfiI-Sall fragment from pREP8 (Invitrogen, San Diego, CA), containing the HisD expression cassette, was first ligated with a 5.9 kb XbaI-Sall vector fragment from pNEF1 [US Patent 5,888,809] and an 823 bp SfiI-XbaI fragment from pNEF1. The three-way ligation was necessary because pNEF1 has an additional SfiI site in the CHEF1 promoter, just upstream of the gene insertion site. The plasmid created by this three-piece ligation was named pHLEF1.

EXAMPLE 2

PRE-SELECTION FUSION: FUSION OF CHO CELLS EACH COMPRISING SINGLE ANTIBODY SUBUNIT BEFORE SELECTION OF HIGH PRODUCING CELLS

[0063] To produce a monoclonal antibody IC14, CHO cells expressing the monoclonal antibody IC14 light chain or heavy chain peptides were fused. IC14 is a recombinant chimeric (murine/human) monoclonal antibody (mAb) recognizing human CD14. The murine parent is an Ab designated 28C5 [Leturcq et al., (1996) *J. Clin. Invest.* 98:1533-38]. IC14 is secreted from Chinese hamster ovary cells as an L₂H₂_γ4 immunoglobulin (Ig).

[0064] Generation of CHO Cells Expressing IC14 Light Chain or IC14 Heavy Chain Polypeptide. IC14 heavy chain was inserted into the pDEF14 plasmid while IC14 light chain was inserted into plasmid pNEF5 as follows.

[0065] The pDEF14/IC14.HC.IgG4 plasmid consists of pDEF14 in which a 5.82 kb HindIII-XbaI fragment, consisting of the IC14 heavy chain gene with IgG4 3' flanking sequence (SEQ ID NO: 5), is present within the HindIII-XbaI site of pDEF14, as described in Running Deer et al. (*supra*). The 5.82 kb

sequence contains (1) a HindIII site, (2) an optimized ribosome binding site, (3) the complete coding sequence for the IC14 heavy chain (SEQ ID NO: 6 and 7) and signal sequence, and (4) 4.2 kb of DNA from the 3' flanking region of the human IgG4 gene [Allison et al, *BioProcessing J.* (2003) Mar/Apr:33-40]. Construction of this plasmid was done using standard methods known in the art, and facilitated by the restriction site AgeI, present within the region encoding the CH1 domain of the IgG4 constant sequence, and an NsiI site, present within the region encoding the CH3 domain.

[0066] The pNEF5/IC14.LC. plasmid consists of pNEF5 in which a 1.05 HindIII-XbaI fragment, containing the IC14 light chain gene with human kappa 3' flanking sequence present within the HindIII-XbaI site of pNEF5. The 1.05 kb sequence (SEQ ID NO: 8) contains (1) a HindIII site, (2) an optimized ribosome binding site, (3) the complete coding sequence for the IC14 light chain (SEQ ID NO: 9 and 10) and signal sequence, and (4) 299 bp of DNA from the 3' flanking region of the human Kappa gene (Allison et al., *supra*). Plasmid DNA of pNEF5/IC14.LC and pDEF14/IC14.IgG4 was prepared using QIAGEN maxi prep kits (Qiagen, Inc., Valencia, CA), according to the manufacturer's instructions.

[0067] Transfection of CHO DG44 cells. Two separate transfections were performed, a first transfection introducing only the heavy chain plasmid into CHO cells, and a second transfection introducing only the light chain plasmid into a second set of CHO cells. Before transfection, untransfected CHO DG44 cells were cultured in HT+ medium [DMEM/F12 medium (BioWhittaker, Walkersville, MD) supplemented with hypoxanthine (0.01 mM), thymidine (0.0016 mM), and 5% - 10% dialyzed fetal bovine serum (FBS) obtained either from JRH Biosciences (Lenexa, KS) or Hyclone (Logan, UT)]. Two days prior to transfection, 100% confluent DG44 cells were plated at 1:16 in T150 (Corning) flasks in 40 mL HT+ medium. On the day of transfection these cells were approximately 50 – 60% confluent.

[0068] Prior to transfection, 50-100 µg of the plasmid was linearized by digestion with restriction enzymes PvuI or Ascl. Sonicated salmon sperm DNA (20 µL) was added prior to ethanol precipitation. The DNA pellet was allowed to air dry briefly and resuspended in 350 µL of sterile, distilled water.

Prior to transfection, the DNA was mixed with 450 μ L of sterile 2X HeBS (40 mM HEPES, pH 7.0; 274 mM NaCl; 10 mM KCl; 1.4 mM Na_2HPO_4 ; 12 mM dextrose).

[0069] CHO DG44 cells were harvested by trypsinization and quenched with an equal volume of HT+ medium. Cells were counted using a hemocytometer and 2×10^7 cell per transfection were aliquotted to 15 mL Corning polypropylene tubes. Cells were centrifuged for 5 minutes at 1000 rpm. The medium was aspirated and the cell pellet washed with 10 mL calcium- and magnesium-free phosphate buffered saline (CMF-PBS). Cells were centrifuged again and the PBS aspirated. Each cell pellet was gently resuspended in 0.8 mL of the DNA solution described above. The resuspended cells were transferred to a 0.4 cm gap Gene Pulser cuvette (Bio-Rad, Hercules, CA) at room temperature and placed in a Bio-Rad Gene Pulser electroporation apparatus.

[0070] Cells were electroporated with a capacitor discharge of 960 μ F at 290 Volts. Each cuvette was subjected to one pulse. Time constants varied from 10-11.4 msec. Following electroporation, cells in the cuvettes were allowed to recover at room temperature for 8-10 minutes. Cells were transferred to 15 mL Corning polypropylene tubes containing 10 mL fresh HT+ medium and spun down in a table top centrifuge as above. The medium was aspirated and the cell pellet resuspended in 2 mL HT+ medium, then transferred to a T75 flask containing 20 mL of HT+ medium. Two days following transfection, all cell lines were 90-95% confluent.

[0071] Fusion of CHO cells producing IC14 light or IC14 heavy chain polypeptides. A 37° C water bath was set up in the cell culture hood. One hundred milliliters (100 mL) of serum free HT+ medium was warmed in two 50 mL Corning polypropylene tubes for 30 minutes prior to cell fusion. One mL of PEG 1500 (Roche PEG 50% w/v in 75 mM HEPES) was warmed in a sterile 1.6 mL microfuge tube.

[0072] One T75 flask of each pool of transfected cells, one expressing IC14 heavy chain and one expressing IC14 light chain, was harvested by trypsinization and the cells pooled in a 50 mL Corning polypropylene tube.

Cells were spun down in a tabletop centrifuge for 5 minutes at 1000 rpm, washed 3 times with 25 mL warm (37° C) serum free HT+ medium. The final cell pellet was gently tapped to loosen before addition of PEG.

[0073] Using a 1 mL pipette, 1 mL of warmed PEG was added to the cell pellet, incubated in a water bath, over the course of 1 minute. The pellet was then stirred gently with the 1 mL pipette for another minute. With a fresh 1 ml pipet, 1 mL of warmed serum free HT+ medium was added to the mixture, over the course of one minute. Using a 5 mL pipette, 3 mL of warmed serum free HT+ medium was added to the mixture over the course of 3 minutes. Finally, using a 10 mL pipette, 10 mL of warmed serum free HT+ medium was added to the mixture over the course of 3 minutes. The cells were incubated at 37° C for an additional 5 minutes. The cells were centrifuged as above and the medium aspirated. Cells were resuspended in 2 mL double selection medium HT-/Neo+ [HT+ medium without hypoxanthine/thymidine, plus 800 µg/mL Geneticin® (GIBCO®)]. Cells were plated in two T225 Corning flasks containing 60 mL HT-/Neo+ and allowed to undergo selection for 11 days.

[0074] Very few colonies formed in the pre-selection fusion sample (100 – 150). Those that did form were pooled in a T75 flask, where they reformed colonies instead of forming a lawn. These colonies were pooled in a T25 flask, where again they appeared to reform colonies. This set of colonies was pooled in a fresh T25, and did form a lawn. Cells were slowly expanded to T150 flasks. When the T150 flasks reached 100% confluency, cells were harvested by trypsinization as above and counted on the hemocytometer.

[0075] Cells were subcloned in five 96-well flat bottomed plates containing HT-/Neo+ medium, 1 cell per well. Pooled transfected cells were also plated in 3 wells of a 6-well non-TC treated plate, at 1×10^6 cells per well in BM18 medium [DME/F12 supplemented with soy hydrolysate and ferrous sulfate [Allison et al, *BioProcessing J.* (2003) Mar/Apr:33-40] +10% FBS. The remaining cells were frozen down in HT-/Neo+ medium plus 10% DMSO.

[0076] The 6-well plates were incubated with shaking (approximately 75 rpm) at 37° C, 6% CO₂ for 3 days, then shifted to a 34° C, 2% CO₂ shaking incubator for 3 additional days. Supernatants were spun down and filtered

with a 0.2 µm syringe filter, then analyzed by Protein A assay (Applied Biosystems, Foster City, CA) using the manufacturer's directions to measure assembly of functional antibody.

[0077] Results of the Protein A antibody analysis from three replicate transfection experiments showed that the pooled colonies produced titers of approximately 80 µg/mL IC14 antibody, 80 µg/mL IC14 and approximately 60 µg/mL of IC14 antibody, respectively.

[0078] Single colonies were then chosen at random from the subcloned plates above, after a two week incubation. These single colonies were expanded to 6 well plates, then transferred to non-tissue culture (TC) treated 6 well plates upon reaching 100% confluency. These plates were grown as described above. Antibody titer from single colonies ranged from approximately 20 µg/mL to approximately 90 µg/mL (see Table 1), with an average titer per colony of approximately 54 ± 19 µg/mL.

[0079] These results demonstrate that fusion of the two cells separately transfected with either the heavy chain or light chain of the IC14 antibody produce fully assembled antibody at high titer. This result is contrary to the toxic effect of over-expressed heavy chain on the heavy chain expressing cell observed in other systems.

EXAMPLE 3

POST-SELECTION FUSION: FUSION OF CHO CELLS EACH COMPRISING SINGLE ANTIBODY SUBUNIT AFTER SELECTION OF HIGH PRODUCING CELLS

[0080] It was hypothesized that if cells producing a significant amount of recombinant heavy or light chain protein could be selected before fusion, this would produce larger quantities of assembled product upon fusion of the two high-producing cells. In order to compare the efficacy of antibody chain transfection and recovery of fully assembled recombinant antibody, the ability of CHO cells to produce monoclonal antibody after selection for high expression of the desired protein was tested. This was termed post-selection fusion.

[0081] Light chain and heavy chain expressing CHO cells were generated as described in Example 2. Two days following transfection, one T75 flask of each pool of transfected cells, one heavy chain and one light chain, was harvested by trypsinization and replated in two T225 Corning flasks with appropriate selective medium (HT- or HT+/neo+ respectively); HT- medium (same as HT+ medium without the HT supplement); HT+/Neo+ (same as HT+ medium with the addition of 800 µg/mL Geneticin® (GIBCO®)).

[0082] A 1:100 dilution of each heavy or light chain transfection was also plated to a 10 cm plate for counting total transfectants. Colonies were allowed to form in selective medium for 10 days. The cell line containing only heavy chain developed close to 15,000 total transfectants, while the light chain cell line yielded 96,000 very small colonies. These colonies were harvested by trypsinization, counted on a hemocytometer and plated in 10 cm plates at 1×10^6 cells per plate in the appropriate selective medium.

[0083] When the 10 cm plates were 100% confluent (a comparable cell number to the 95% confluent T75 used for Pre-Selection Fusion), the fusion procedure was done as described above. Following fusion, cells were plated in a T150 Corning flask in HT-/Neo+ double selection medium for 10 days. Cells were fed fresh medium on day 5.

[0084] On day 10, colonies were pooled and replated in fresh T150 Corning flasks. One day later, cells were expanded to two T225 Corning flasks. Two days later, the T225 flasks were 100% confluent. Cells were harvested by trypsinization and counted on the hemocytometer. Cells were subcloned in five 96-well flat bottomed plates, 1 cell per well. Cells were also plated in 6 wells of a 6-well non-TC treated plate, at 1×10^6 cells per well in BM18 +10% FBS medium. The remaining cells were frozen in HT-/Neo+ medium plus 10% DMSO.

[0085] The 6-well plates were incubated with shaking (approx. 75 rpm) at 37° C, 6% CO₂ for 3 days, then shifted to a 34° C, 2% CO₂ shaking incubator for 3 additional days. Supernatants were centrifuged and filtered with a 0.2 µm syringe filter, then analyzed by Protein A assay.

[0086] Results of the Protein A antibody analysis from three replicate transfection experiments showed that the pooled colonies produced IC14 antibody titers of 32.75 µg/mL (SD = 0.65, n = 6), which is comparable to titers of the exact same plasmids when co-transfected in CHO cells using a standard electroporation protocol (36.65 µg/mL, SD = 5.6, n = 6).

[0087] After two weeks, single colonies that formed in the 96 well plates were expanded to 6-well TC treated plates and incubated at 37° C until 100% confluent (about 5 days). These cells were then transferred to 6-well Non-TC treated plates and grown as described above. Antibody titer from single colonies from the post-selection fusion ranged from 0.0 µg/mL in several of the fusants to approximately 60 µg/mL IC14 (see Table 1), with an average titer per colony of approximately 16 ± 17 µg/ mL. When only the clones producing antibody were taken into account, the average antibody titer was 21.2 ± 17 µg/ mL.

[0088] These results show that the fusants coupled after selection of high expressing cells still produced detectable amounts of antibody, though not to the extent of the clones that were not selected before fusion of the two cells (Table 1). This result is contrary to previous theories which suggest that cells overexpressing heavy chain likely would not survive due to the toxicity of the heavy chain protein. However, the pre-selection fusion gave fusants with higher titers which suggests that fusing the transfected cells after selection is disadvantageous in that cell growth may be inhibited by expression of high levels of only the heavy chain or light chain.

TABLE 1

Pre-selection Fusion IC14 Antibody Titers	Post-selection Fusion IC14 Antibody Titers
17.15	0
18.5	0
20.13	0
23.36	0

Pre-selection Fusion IC14 Antibody Titers	Post-selection Fusion IC14 Antibody Titers
29.21	0
31.81	0
40.94	0
43.33	3.82
45.86	4.76
46.38	5.18
47.64	5.32
50.51	5.95
50.75	6.69
53.3	7.55
54.56	8.29
54.8	8.87
56.02	13.31
57.72	19.88
61.53	20.01
63.02	20.16
68.03	20.26
68.95	21.24
71.83	22.09
72.45	28.94
72.47	29.47
74.88	31.07
78.02	40.41

Pre-selection Fusion IC14 Antibody Titers	Post-selection Fusion IC14 Antibody Titers
78.79	43.27
84.66	58.77
88.2	62.1
Average: 54.16 $\pm$ 20	Average: 16.25 $\pm$ 17.3

[0089] Overall, these experiments demonstrate that fusion of two separate cells each expressing a different subunit of a heteromultimeric protein, in each case under the control of the CHEF-1 transcription regulatory DNA, generates functional multimeric protein. These results showed that chemical amplification of the gene is not required to get high levels of gene expression before or after fusion of the cells of interest. Moreover, absence of the amplifying agent provides a less toxic environment for the cells to grow and may avoid the high incidence of the fusants eventually becoming low level expressers over time [Strutzenberger et al., *J. Biotechnol.* (1999) 69:215-26].

[0090] Numerous modifications and variations in the invention as set forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

WHAT IS CLAIMED IS:

1. A method for making a multimeric protein comprising the steps of:
 - a) transfecting a first host cell with a first plasmid comprising a first polynucleotide encoding a first polypeptide of the multimeric protein, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the first polypeptide;
 - b) transfecting a second host cell with a second plasmid comprising a second polynucleotide encoding a second polypeptide of the multimeric protein, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the second polypeptide;
 - c) fusing the host cells to make a cell hybrid, wherein the cell hybrid expresses the polypeptides comprising the multimeric protein, and
 - d) culturing the cell hybrid in culture media under conditions that permit the expression and association of the polypeptides to form the multimeric protein.
2. The method of claim 1 further comprising an additional transfection step of an additional host cell for each additional polypeptide of the multimeric protein.
3. The method of claim 1 wherein the multimeric protein is a monoclonal antibody, a humanized antibody, a human antibody, a chimeric antibody, a bifunctional/bispecific antibody, a complementarity determining region (CDR)-grafted antibody, a Fv fragment, a Fab fragment, a Fab' fragment, or a F(ab')₂ fragment.
4. The method of claim 3 wherein the first polynucleotide encodes an antibody heavy chain polypeptide or variant or fragment thereof.

5. The method of claim 3 wherein the second polynucleotide encodes an antibody light chain polypeptide or variant or fragment thereof.
6. The method of claim 1 wherein the regulatory DNA is CHEF1 transcription regulatory DNA, a MAR element, or a ubiquitous chromatin opening element (UCOE).
7. The method of claim 6 wherein the regulatory DNA is CHEF1 transcription regulatory DNA.
8. The method of claim 1 wherein the first or second plasmid is pNEF5, pDEF14, pDEF2, pDEF10, pDEF38, pNEF38, or pHLEF38.
9. The method of claim 1 wherein the first host cell and the second host cell are the same type of cell.
10. The method of claim 1 wherein the first host cell and the second host cell are mammalian cells.
11. The method of claim 10 wherein the first host cell and second host cell are CHO cells.
12. The method of claim 1 wherein the step of fusing the first host cell and the second host cell is performed without first selecting for host cells expressing the individual polypeptide using appropriate selective media.

13. The method of claim 1 further comprising before step (c) , and after step (a) the step of: selecting a first host cell expressing the first polypeptide by culturing under conditions that permit polypeptide expression prior to the fusing step.

14. The method of claim 1 further comprising before step (c) , and after step (b) the step of: selecting a second host cell expressing the second polypeptide by culturing under conditions that permit polypeptide expression prior to the fusing step.

15. The method of claim 1 further comprising before step (c) , and after step (a) and step (b) the steps of:

selecting a first host cell expressing the first polypeptide by culturing under conditions that permit polypeptide expression prior to the fusing step, and

selecting a second host cell expressing the second polypeptide by culturing under conditions that permit polypeptide expression prior to the fusing step.

16. A method for making an antibody comprising the steps of:

a) transfecting a first host cell with a first plasmid comprising a first polynucleotide encoding a heavy chain polypeptide of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the heavy chain polypeptide;

b) transfecting a second host cell with a second plasmid comprising a second polynucleotide encoding a light chain polypeptide of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the light chain polypeptide;

c) fusing the host cells to make a cell hybrid, wherein the cell hybrid expresses the heavy chain polypeptide and the light chain polypeptide, and

d) culturing the cell hybrid in culture media under conditions that permit the expression and association of the heavy chain and the light chain to form the antibody.

17. The method of claim 16 further comprising, before step (b) the step of: (b') transfecting a third host cell with a third plasmid comprising a third polynucleotide encoding a J chain of the antibody, wherein the plasmid is not amplified using an amplifiable marker and wherein the plasmid comprises a selectable marker and a regulatory DNA element which provides increased expression of the light chain.

18. The method of claim 17 wherein the fusing step b) comprises (i) fusing the transfected host cells obtained from any two of the transfecting steps (a), (b) and (b') to form an intermediate fusant and (ii) fusing the intermediate fusant with the transfected host cells obtained from the remaining transfecting step (a), (b), or (b') not fused in (i) to obtain the cell hybrid.

19. The method of claim 16, wherein the antibody is an Fab fragment, and the heavy chain polypeptide and the light chain polypeptide are fragments capable of permitting expression and association of the Fab fragment.

SEQUENCE LISTING

<110> Allison, Daniel

<120> Recombinant Method for Making Multimeric Proteins

<130> 27866/40433A

<150> 60/634,355

<151> 2004-12-08

<160> 10

<170> PatentIn version 3.3

<210> 1

<211> 3678

<212> DNA

<213> Cricetulus griseus

<400> 1

```

actagttcca aagatgaatt actaaccagt gtttccaagg aaataaatga aagcagagag      60
attagttcta ttgctagtgt ttcattttcg tatatttctt acaatttctc ttgttacaaa      120
taggcactag ggtatcaaga taattttaac gactggctga gaaccctaga aaatctctgt      180
gaaaaagggg tttgtgaaat gagagagggg aatgtggcca ttatagaaaa ggcttttgtg      240
tgccttgcac gcatagaccc tgtgtttgat ctcttaacac cctccttgac cagaaaaagc      300
ttctgtggat agaaaatgat tagttatata tacttttagg gaaacgtagt tctggattct      360
ttggttacaa ttaacagaat taagtgcaca caaagccaga aacctcctga taaatgagaa      420
aacctgcttg tagaagggtg taaggctctg taatatagga attaggagaa aagaaacctg      480
tgtggtgggg cacgtctgta atcccagcat tgggaagtag aggtagaaga ttagaaatca      540
aaggccagcc tcagcaacac agtgagtttg aggccaccct gaactacatc aggttctgtc      600
tcctttcttt tttttttttt tttcttttct ttttttgggt tctctgtgta gttttggagc      660
ctatcctggc actagctctg aagagcaggc tggcctcgaa ctgagagatc agccagcctc      720
tgctgggatt aaaggtatgc accaccaacg ccccagggtt tgtctcaaac aaacaaaaat      780
aacatcagga ggtggtgaga gggctcagtg gtcacaggca ttctctgcaa agcctgactc      840
tgagttggat ccttttagagc tacatggttg agggaagaga actgactcct ggaaggtgtc      900
ctctggtccc cacacatagc tatacacagc atgtgcattc acacacacta aataatgcta      960
tttttaaaaa aattaaaaac aacaacagtt tgggttggtg aaactagaac tagataatag     1020
gtaagaatca agtatcatgt aaatttgctt tcaactcatc ccaaaatttg ttttatattt     1080
cagttttttt ccttcctagc ttgactgtgg agtcttgtcc ggaagcaaag agttcctttg     1140
cagatcccac atgtggacac cggacagtag gtcctcaaag gtccttattt aggttggttc     1200
aataatatca attgtttggt actaggcagt gatgttgtac atctggagga gatctcttga     1260

```

gcccataatc aggttattag gaataaatac tctaaggcta aaaatgtagc ttagtgataa	1320
gagtgccttgc ctggtgtgct gagaccctcg gttccatctc cacaacccca tattccatta	1380
caaaataacct tttcacctgc cctagcatta agaaacaaaa caacaaagaa gtttttcttt	1440
cttctgagat cctgcccgga gaggcattta aaactggcca gggccaaaaa aaaaaaaaaa	1500
aaaagaaaaa aaagaaaaga aaacaggcta gggccggcat ggtggcgcac gcctttaatc	1560
ccagcacgca ggaggcagag gcaggcgga tctctgtgag tttgaggtca gcctggtcta	1620
cctagtgagt ttcagggcac ccagggctaa agagactgtc tcaaaaacaa aacagccaca	1680
caatcagaac cacagcaaaa cgcagttatg atccttggaa ctgtaggaat gacaagcatt	1740
taaataatag gacgagccat ttttgagaag ctctgatttc acaagtgtca gggatgggct	1800
ctgggcgagt aagattgcta atgctggcct ctaaatgaga ccacgtggag ttgattagat	1860
tcttttcatg ttctctgtgc tctatcaaat aactgtacct aaatacacac acacacacac	1920
acacacacaa tgcgcgcaca caaaaatcc ttttttagct taagaagccc agaatcagaa	1980
gtaaagctaa ctgtgggact taagtattat tctgaacgga actcccaggg cgtgaagcgc	2040
gcttcaggct tccagagaag cagctggcgc tggatggaat gaaccaagag gccagcacag	2100
gggcagatcc gtcgagctct cggccaccga gctgagccct taggttctgg ggctgggaag	2160
ggtccttagg attgtgcacc tctcccgcg gggacaagca ggggatggcg gggctgacgt	2220
cgggagggtg cctccacggg aagggaacac cggatctcga cacagccttg gcagtggagt	2280
caggaagggg aggacagatt ctggacgccc tcttggccag tcctcaccgc cccacccccg	2340
atggagccga gagtaattca taaaaagga gggatcgctc tcgcccctgg gaatcccagg	2400
gaccgtcgct aaattctggc cggcctccca gcccggaacc gctgtgcccg ccagcgcgg	2460
cgggaggagc ctgcgccctag ggcggatcgc gggtcggcgg gagagcaca gcccacagtc	2520
cccggcggtg ggggaggggc gcgctgagcg ggggcccggg agccagcgcg gggcaaactg	2580
ggaaagtggg gtcgtgtgct ggctccgccc tcttcccag ggtgggggag aacggtataa	2640
aagtgcggta gtcgcgttgg acgttctttt tcgcaacggg tttgccgtca gaacgcaggt	2700
gagtggcggg tgtggcctcc gcgggcccgg gctccctcct ttgagcgggg tcggaccgcc	2760
gtgcgggtgt cgtcggccgg gcttctctgc gagcgttccc gccctggatg gcgggctgtg	2820
cgggagggcg agggggggag gcctggcggc ggccccggag cctcgcctcg tgtcgggcgt	2880
gaggcctagc gtggcttccg ccccgcccg tgccaccgcg gccgcgcttt gctgtctgcc	2940
cggctgccct cgattgcctg cccgcggccc gggccaacaa agggagggcg tggagctggc	3000
tggtagggag ccccgtagtc cgcagtgcgg gcaggagag cggcagcagt cggggggggg	3060
accgggcccg cccgtcccgc agcacatgtc cgacgccgcc tggacgggta gcggcctgtg	3120
tcctgataag gcggccgggc ggtgggtttt agatgccggg ttcaggtggc cccgggtccc	3180

```

ggccccgtct ggccagtacc ccgtagtggc ttagctccga ggagggcgag cccgcccgcc 3240
cggcaccagt tgcgtgcgcg gaaagatggc cgctcccggg ccctgtagca aggagctcaa 3300
aatggaggac gcggcagccc ggcgga'cg'g gg'cg'ggtgag tcacccacac aaaggaagag 3360
ggccttgccc ctgcgccggc gctgcttcct gtgaccccg'g ggtgtaccgg ccgcacttca 3420
gtcacc'cc'gg g'cg'ctctt'c ggagcaccgc tggcctccgc tgggggaggg gatctgtcta 3480
atggcg'tt'g ag'tt'tgctca catttgg'tg gtggagactg tagccaggcc agcctggcca 3540
tggaagtaat tctt'ggaatt tgcccattt'c gag'tt'tggag cgaagctgat tgacaaa'gct 3600
gcttagccgt tcaaaggtat tcttcgaact ttttttttaa ggtgtt'gtga aaaccaccgc 3660
taattcaaat ccaacatg 3678

```

```

<210> 2
<211> 4072
<212> DNA
<213> Cricetulus griseus

```

```

<400> 2
gtgcatagaa acagatgcag gcaaaacatc cacacatata aaacaaaaaa ttaaaaccaa 60
taaaactcct aaactttt'gg tctttctt'ga atcttcaatc cctcagg'tta tgaaataatc 120
at'ttatgcag tcaaaaattt gccattct'tg ttgccagg'tg tgg'tgatgat t'cg'gggaagc 180
agaagcaggc agatctctgt gaatgaggcc agcctgg'tct acaaag'tgag tcccaggaca 240
gtcaggcctg ttacacagag aaaccttgaa aaaaaaa'ga taatatgtac tgtt'gtatta 300
ccccaatata taaggctaaa ccattagaag cacaacactg ttaagtacgg aaaataatat 360
ctagtgtgg't acagttacta ctactataat acactaatat agctgtggga aactagt'tcc 420
aaagatgaat tactaaccag tgtttccaag gaaataaatg aaagcagaga gattagt'tct 480
attgctagt'g tttcattt'c gtatattt'ct tacaattt'ct cttgtt'acaa ataggcacta 540
gggtatcaag ataatttt'aa cgactgg'ctg agaaccctag aaaatctctg tgaaaaaggg 600
at'tt'gtgaaa tgagagaggg taatgtggcc attatagaaa aggctt'tt'gt gtgccttgca 660
tgcatagacc ctgtg'tt'ga tctcttaaca ccctccttga ccagaaaaag cttctgtgga 720
tagaaaatga ttagttatat atactttt'ag ggaaacgtag ttctggattc tttggttaca 780
attaacagaa ttaagt'caa acaaagccag aaacctcctg ataaatgaga aaacctg'ctt 840
gtagaagg'tt gtaaggctct gtaatatagg aattaggaga aaagaaacct gtgtgg'tggg 900
gcacgtctgt aatcccagca ttgggaag'ta gaggtagaag attagaaatc aaaggccagc 960
ctcagcaaca cagtga'g'tt'c gaggccaccc tgaactacat cagg'tt'ctgt ctcc'tt'ctt 1020
ttttttttt'c ttttctt't'c tttttt'gg't ttctctgtgt ag'tt'tt'ggag cctatcctgg 1080
cactagctct gaagagcagg ctggcctcga actcagagat cagccagcct ctgctgggat 1140

```

taaaggtatg caccaccaac gccccaggtt ttgtctcaaa caaacaaaaa taacatcagg	1200
agggtggtgag aggggtcaggt ggtcacaggc attctctgca aagcctgact ctgagttgga	1260
tccttttagag ctacatgggt gaggaagag aactgactcc tggaaggtgt cctctgggtcc	1320
ccacacatag ctatacacag catgtgcatt cacacacact aaataatgct attttttaaaa	1380
aaattaaaaa caacaacagt ttgggttggtg aaaactagaa ctagataata ggtaagaatc	1440
aagtatcatg taaatttgct ttcaactcat cccaaaattt gttttatatt tcagtttttt	1500
tccttcctag cttgactgtg gagtcttgct cggaagcaaa tagttccttt gcagatccca	1560
catgtggaca cgggacagta ggtcctcaaa tgctccttat taggttggtt caataatatc	1620
aattgtttgt tactaggcag tgatgttgta catctggagg agatctcttg agcccataat	1680
caggttatta ggaataaata ctctaaggct aaaaatgtag cttagtata agagtgtttg	1740
cctggtgtgc tgagaccctc ggttccatct ccacaacccc atattccatt acaaaatacc	1800
ttttcacctg ccctagcatt aagaaacaaa acaacaaaga agtttttctt tcttctgaga	1860
tcctgcccgg agaggcattt aaaactggcc agggccaaaa aaaaaaaaaa aaaaagaaaa	1920
aaaagaaaag aaaacaggct agggccggca tgggtggcgca cgcctttaat ccagcacgc	1980
aggaggcaga ggcagggcgg atctctgtga gtttgaggtc agcctggtct acctagttag	2040
tttcagggca ccagggcta aagagactgt ctcaaaaaca aaacagccac acaatcagaa	2100
ccacagcaaa acgcagttat gatccttgga actgtaggaa tgacaagcat ttaaataata	2160
ggacgagcca tttttgagaa gctctgattt cacaagtgtc agggatgggc tctgggagag	2220
taagattgct aatgctggcc tctaaatgag accacgtgga gttgattaga ttcttttcat	2280
gttcctcgtg ctctatcaaa taactgtacc caaatacaca cacacacaca cacacacaca	2340
atgcgcgcac acacaaaatc ctttttttagc ttaagaagcc cagaatcaga agtaaagcta	2400
actgtgggac ttaagtatta ttctgaacgg aactcccagg gcgtgaagcg cgcttcaggc	2460
ttccagagaa gcagctggcg ctggatggaa tgaaccaaga ggccagcaca ggggcagatc	2520
cgtcgagctc tcggccaccg agctgagccc ttaggttctg gggctgggaa ggtccctag	2580
gattgtgcac ctctcccgcg ggggacaagc aggggatggc ggggctgacg tcgggaggtg	2640
gcctccacgg gaagggacac ccgatctcg acacagcctt ggcagtggag tcaggaaggg	2700
taggacagat tctggacgcc ctcttgcca gtcctcaccg cccaccccc gatggagccg	2760
agagtaattc atacaaaagg agggatcgcc ttcgcccctg ggaatcccag ggaccgtcgc	2820
taaattctgg ccggcctccc agcccgaac cgctgtgccc gccagcgcg gcgggaggag	2880
cctgcgccta gggcggtatc cgggtcggcg ggagagcaca agcccacagt ccccgcggt	2940
gggggagggg cgcgctgagc gggggcccg gagccagcg ggggcaaaact gggaaagtgg	3000
tgctcgtgtc tggctccgcc ctcttccga ggggtggggga gaacggtata aaagtgcggt	3060

agtcgcgttg gacgttcttt ttcgcaacgg gtttgccgtc agaacgcagg tgagtggcgg 3120
 gtgtggcctc cgcgggcccc ggctccctcc tttgagcggg gtcgggcccc cgtgcgggtg 3180
 tcgtcggccg ggcttctctg cgagcggttc cgccttgat ggccggctgt gcgggagggc 3240
 gaggggggga ggctggcgg cggccccgga gcctcgctc gtgtcgggcg tgaggcctag 3300
 cgtggcttcc gccccgccc gtgccaccgc ggccgcgctt tgctgtctgc ccggctgccc 3360
 tcgattgcct gccccgggc cgggccaaca aaggaggggc gtggagctgg ctggtaggga 3420
 gccccgtagt ccgcatgtcg ggcagggaga ggcgcagcag tcgggggggg gaccgggccc 3480
 gcccgtccc cagcacatgt ccgacgccgc ctggacgggt agcggcctgt gtcctgataa 3540
 ggccggccgg cggtgggttt tagatgccgg gttcaggtgg ccccggtcc cggcccggtc 3600
 tggccagtac ccgtagtggt cttagctccg aggagggcga gcccggccc cgggcaccag 3660
 ttgctgtcgc ggaaagatgg ccgctcccg gccctgtagc aaggagctca aaatggagga 3720
 cgccgcagcc cggcggagcg gggcgggtga gtcaccaca caaaggaaga gggccttgcc 3780
 cctcgccggc cgctgcttcc tgtgacccc tgggtgtacc gccgcacttc agtcacccc 3840
 ggcgctcttt cggagcaccg ctggcctccg ctgggggagg ggatctgtct aatggcgttg 3900
 gagtttgctc acatttggtg ggtggagact gtagccaggc cagcctggcc atggaagtaa 3960
 ttcttggaat ttgccattt tgagtttgga gcgaagctga ttgacaaagc tgcttagccg 4020
 ttcaaaggta ttcttcgaac ttttttttta aggtgtgtg aaaaccaagc tt 4072

<210> 3
 <211> 4183
 <212> DNA
 <213> *Cricetulus griseus*

<400> 3
 ccatttaagt ttaatagtga aagactgggt aatgataaca atgcatcgga aaaccttcag 60
 gaggaagga gaatgttttg tggaacattt ttgtgtgtgt ggcagtttta agttattagt 120
 tttcaaaatc agtacttttt aatggaaaca acttgaccaa aaatctgtca cagaattttg 180
 agaccatta aaatacaagt ttaatgagaa gtctgtctct gttaatgctg aagtcattac 240
 taagtgttta gcttagcaag gtatgtggat gccatttgt gttccaaggg attggactgt 300
 tcatcaggac ccagagctga gtttcaaggg ctcaagagat ggcttattac ctgtgggtgt 360
 cttgaagggt ctggttgga caaattagga atgtttttgg cagacatggt gactaccttc 420
 atctgggtga gttcagttga tttgtcttga gcctttgggg ttacacaag taaatgacat 480
 catacagtta gtgtattgtt agtgaatatt aatatatgag gcaggctttg ctctagcaat 540
 tttagaacta gttttcagga aagggttcat cttgtgcatt ggatgtttga ttctatcact 600
 tagagtttaa actgaaagt ctcaagaggt tttatttagg ctgggatata aataagcctt 660

tctgtagctt	gtaatggtat	caggaattta	aaaggccatc	tggggcacia	agattaagca	720
gaaaaggtag	aaggtgagat	tgggggactt	tgagtacttc	acacacttta	atgtgtgagt	780
gcttttagtgc	atatagtaca	actgccagat	aagggcatcc	acatctgatt	gtttggaagg	840
caccttgtgg	tttctgggaa	ttcagaattg	ggagaaaaat	gtccccaacc	gctgaagccc	900
ttggtaatct	gcaggggtgtt	tatttagcag	gagataagga	caaaaagtta	tagtgtggag	960
ttggttgagt	tggtagatgt	cattacaaca	ggtggtctta	aattgggtta	ggagtcactt	1020
tgaaataacct	gggcataag	caaagtggca	ttttcacctt	tcaggagaaa	ctggtacact	1080
tatccattct	atagtgcatt	cttgttcaat	tgggctgatg	actaaaccgg	tgactaaagg	1140
tttgtcagta	taaatggatg	ggttgtaggc	agacggtgag	gaattactat	acctgcaagg	1200
agtcattgcc	tgatctgcct	ggaaaggggc	aggattgagt	ctcagaacgt	gtacaccata	1260
ggatatggaa	aaatttgtca	cgcctagcat	tcaacttagt	ggtgtagcgc	cacctactgg	1320
cactttaaaa	gcttagcata	gaggagcatg	tgtgttagga	gctcggatgg	gatccagggc	1380
ctcaagggtt	gcatgtaaat	aaaagccctt	taccaaatta	actacatacc	agcatacatc	1440
agtccttttag	tgttgaaaaa	cagaaggga	agctaataata	tatagtgtct	gctttattta	1500
agtctagctg	attacgtgtt	tggttgccag	tgtgactagt	ctggagttga	atttgtcctc	1560
agacacgtaa	aatggaattt	gggattcaca	acactctagt	atgagggacc	taatggcctg	1620
taccaggcac	aaacgtgtct	ataaactaca	caaacgaag	gaatttacag	gaattaggaa	1680
ggtattctta	acattaaaac	attatgggca	ttttaaaaaa	agctttgaca	ggatttcttt	1740
gtcatggctg	tcctggagct	agttgtgtag	accaggctgg	gctgaaatct	tgtctgcctg	1800
cctggcttgg	acactttttt	attatgtata	caacattctg	cttccatgta	tatctgcaca	1860
ttagaagacg	gcaccagatc	tcctaattga	tggttgtgag	ccaccatgtg	gttgtctggga	1920
attgaactca	ggacctctgg	aagagcagtg	ctcttaacct	ctgagccatc	tccagcccca	1980
gcttgggcac	attttttaatg	gctgggaaat	caaaccctct	aggccttctg	tcagtaatga	2040
agggcctttt	gctaccgaga	gtaggattta	aggttattcg	gagctgcagg	tctgcctcag	2100
tgagggtttg	ggagtccagc	atcttagaaa	atgcagtga	gccaagctga	gctatatattt	2160
gttttaaaaa	aaaataagtg	ggtaaagtgc	tgctgagcct	gatgaccaag	ctgggacaca	2220
agtagaagaa	cataggccaa	tgctctatat	taaaagcatg	ggtcattttt	aatgctcttg	2280
agaaggctat	gcctacacta	ctctcagcca	ccgcagcgtg	tttaaattaa	actagttttg	2340
aaattttctt	tgggggtaag	ctatttaacc	tagtgccttg	gcagggtatac	tactgaactc	2400
tcctcctcat	tcctttttgt	tttttaagaa	tttcagtcag	gctcaggcag	cccttaaaact	2460
tgtgattaag	cctgagaaca	gttacgatta	tgagcctatt	agtataccga	tcaatatgtg	2520
aatttttttg	ggatgggggt	caggcctccc	tgctcccaa	atactgggac	taaaggctgc	2580

```

accaccacaa cctggctctt gaaatacttt tctacatttt ttgggggggca tgggtgggag 2640
agcaggggttt ctctgtatta gccctggctc tcctggaact ctgtagacca ggctattctt 2700
gagctcagat tagcctgtct ctgcctccta aattctggga ttaaagggtgt gtgctactgc 2760
tgcttggtta caaagacatt tttttttttc ttaaatttaa aaacaaaagt ggttctttta 2820
gaaggggtgt tgggtgttggc acatactcca agcactcagg ttttgagttt gtcccaggaa 2880
tgaagactgc attactgccg cccctccctg gtaagggtta cacagagaaa tcctatttgg 2940
agcctatcct ggtaactcgc tctgtagacc aggctggcct cgaactcaag agaaccacct 3000
gcctctgaat gctggtatta agggcaggca ccaccaacac ccagcctaaa aaatgtcttt 3060
tttttaaaga tttttttttt tttttttaca gaataaacat tctgtttaca atattctgct 3120
tctatgtata tctgcacact agaagagggc acccgatctc ataatggatg gttgtgagcc 3180
accaagtgtt tgctgggaat tgaactcaga acctctggaa gagcagtcag tgctcttaac 3240
ctctgagcca tctctccagc ccctaaaaat ggctcttgag ataggggtctc aagtagtttg 3300
agactgagtt ggctatataa acaaggctgg cacatagcac catgtacagc tgggtttagt 3360
ttacatgggg tgtttttgtc tctggaggca ggaggatcat ttgagcatag ggagttaata 3420
gtgaggtcat gttttatcta ctcttctgaa ttgagaacta agctgatgca aagcaagttt 3480
gactgaagaa gtccagttta tgagaacaag ggtggaaact aatgtgtcaa agatggcctt 3540
gcatgtgttt tagatgatga cccagtcact tgggaattac tggatgtgta agacctatat 3600
cttgacagga gtgaacagtg tcttataggt cctatatgaa agaaatgaga cataccatt 3660
ttgtttcccc taagaattca cttttcctaa cctgggtcat gctatttagg ttattttact 3720
tgcaaatcct aggtgctccc ttaccagta ttgcttatgt ggcaccaaag tcactcactc 3780
ccatgatttg caagtctctg ggaacttcca tgacaaccta gaatagcaac tcaaatacat 3840
tttctcagta ccaattttga agaaaaata ttttgcaaaa tagctgtatg gatgggtact 3900
aaatagtgag gttatctcca gaaggcctat gaagaattaa gggtgagttc agttgagttc 3960
agcagcaagt ttaaggttca tccatttttg tacagtgttt tcctattacg gtaagtgttt 4020
tgctgcagg aatatctgta ccacatgctt gcctgttacc tatatcggcc agaagagggc 4080
tttgatcct ctggacttga attacagatg ggtattagcc accatttagg tgctgggaat 4140
tgaaaccaag tcctctggaa gaacagcaag tgatcgagtc gac 4183

```

<210> 4
 <211> 56
 <212> DNA
 <213> Artificial

<220>
 <223> synthetic nucleotide

<400> 4
aagcttcaag ttatgctcta gaatccggta cctcgagaaa atgcatggca gtcgac 56

<210> 5
<211> 5823
<212> DNA
<213> Artificial

<220>
<223> synthetic nucleotide

<400> 5
aagcttgccg ccaccatgaa agtggtgagt ctgttggtacc tggtgacagc cattcctggc 60
atcctgtctg acgtacagct tcagcagtcg ggacctggcc tggtgaaacc ttctcagctc 120
ctgtccctca cctgcactgt cactggctac tcaatcacca gtgattctgc ctggaactgg 180
atccggcagt ttccaggaaa cagactggag tggatgggct acataagcta cagtggtagc 240
actagctaca acccatctct caaaagtcga atctctatca ctcgagacac atccaagaac 300
cagttcttcc tgcagttgaa ctctgtgact actgaggaca cagccacata ttactgtgta 360
agagggctcc ggtttgctta ctggggccaa gggactctgg tcaactgtgag ctgagctagc 420
accaagggcc catccgtctt cccctggcg cctgtctcca ggagcacctc cgagagcaca 480
gccgccctgg gctgcctggc caaggactac ttccccgaac cggtgacggc gtcgtggaac 540
tcaggcgccc tgaccagcgg cgtgcacacc ttcccggtg tcctacagtc ctcaggactc 600
tactccctca gcagcgtggc gaccgtgccc tcagcagct tgggcacgaa gacctacacc 660
tgcaacgtag atcacaagcc cagcaacacc aagggtggaca agagagttga gtccaaatat 720
ggtcccccac gcccatcatg cccagcacct gagttcctgg ggggaccatc agtcttctctg 780
ttcccccaa aaccaagga cactctcatg atctcccgga cccctgaggt cacgtgcgtg 840
gtgggtggacg tgagccagga agaccccgag gtccagttca actggtacgt ggatggcgtg 900
gaggtgcata atgccaagac aaagcccgcg gaggagcagt tcaacagcac gtaccgtgtg 960
gtcagcgtcc tcaccgtcct gcaccaggac tggctgaacg gcaaggagta caagtgcaag 1020
gtctccaaca aaggcctccc gtctccatc gagaaaacca tctccaaagc caaagggcag 1080
ccccgagagc cacaggtgta caccctgccc ccatcccagg aggagatgac caagaaccag 1140
gtcagcctga cctgcctggc caaaggcttc taccacagcg acatcgccgt ggagtgggag 1200
agcaatgggc agccggagaa caactacaag accacgcctc ccgtgctgga ctccgacggc 1260
tccttcttcc tctacagcag gctaaccgtg gacaagagca ggtggcagga ggggaatgtc 1320
ttctcatgct ccgtgatgca tgaggctctg cacaaccact acacacagaa gagcctctcc 1380
ctgtctctgg gtaaagtgt gccagggccg gcaagcccc gctccccggg ctctcggggc 1440
cgcgcgagga tgcttggcac gtaccccgtc tacatacttc ccaggcacc agcatggaaa 1500

taaagcacc	accactgcc	tgggcccctg	tgagactgtg	atggttcttt	ccacgggtca	1560
ggccgagtc	gaggcctgag	tgacatgagg	gaggcagagc	gggtcccact	gtccccacac	1620
tggcccaggc	tgtgcaggtg	tgcctggggc	acctaggggtg	gggctcagcc	aggggctgcc	1680
ctcggcaggg	tgggggattt	gccagcgtgt	ccctccctcc	agcagcagct	gccctgggct	1740
gggccacggg	aagccctagg	agcccctggg	gacagacaca	cagcccctgc	ctctgtagga	1800
gactgtcctg	tcctgtgagc	gccctgtcct	ccgaccccc	atgccactc	gggggcatgc	1860
ctagtccatg	tgcgtaggga	caggccctcc	ctcaccatc	tacccccacg	gcactaacc	1920
ctgtctgccc	tggccagcct	cgcaccgcga	tggggacaca	accgactccg	gggacatgca	1980
ctctcggggc	ctgtggaggg	actggtgcag	atgccacac	acacactcag	cccagaccgg	2040
ttcaacaaac	cccgcactga	ggttggccgg	ccacacggcc	accacacaca	cacgtgcacg	2100
cctcacacac	ggagcctcac	ccgggcgaac	cgcacagcac	ccagaccaga	gcaaggtcct	2160
cgcacacgtg	aacactcctc	ggacacaggc	ccccacgagc	cccacgcggc	acctcaaggc	2220
ccacgagccg	ctcggcagct	tctccacatg	ctgacctgct	cagacaaacc	cagccctcct	2280
ctcacaaggt	gcccctgcag	ccgccacaca	cacacagggg	aacacacgcc	acgtcgcgtc	2340
cctggcactg	gcccacgtcc	caatacagcc	cttccctgca	gctgggggtca	catgaggggt	2400
gggtttcacc	atcctcctgc	cctctggggc	tcaggagggg	acacgggaga	cggggagtgg	2460
gtcctgctga	gggccaggtc	gctatctagg	gccgggtgtc	tggctgagcc	ccaggggcaa	2520
agctgggtgc	cagggtggac	agcttcggg	agctgacctc	aggacattgt	tggcccatcc	2580
cggccggggc	ctacatcctg	ggccccgcca	cagagggaat	cacccccaga	ggcccaagcc	2640
cagggggaca	cagcactgac	cacccccttc	ctgtccagag	ctgcaactgg	aggagagctg	2700
tgcggaggcg	caggacgggg	agctggacgg	gctgtggacg	accatcacca	tcttcatcac	2760
actcttcctg	ctaagcgtgt	gctacagtgc	caccgtcacc	ttcttcaagg	tgggccgcac	2820
gttgtcccca	gctgtccttg	acattgtccc	ccatgctgtc	acacactgtc	cctgacactg	2880
tccccactc	tctccacaaa	ctgtccctga	cactgtcccc	catgctgtac	acacctgtcc	2940
aacagtgtcc	cccaggctgt	ctccacatgt	ccgacactgt	cccccatgct	atccccatc	3000
ctgacactgt	ccccacact	gtccccacct	gtccttgatg	ctgtgcccc	cggctctccc	3060
acctctccct	gattctgtcc	cccacgtgt	acctgtcccc	aatgctctcc	cccagcctgt	3120
ccccaacact	gtccgccatg	ctgtcccacc	tttccccac	actgtcccc	agtctccgcc	3180
tgtccctgac	gctgtcccac	atgcgggtcc	ccattcctga	aactgtcccc	catgctgtcc	3240
ccaccttccc	caacactgta	ccccacagtc	cccaccttcc	ccaacactgt	ccccacctgt	3300
ccctgacact	cccccatgct	gtccccacct	gtccccact	cacccccac	actgtcccta	3360
cctgtctctg	acactgtccc	ccatgctgtc	cgcacctgtc	cccgcccc	acgctgtccc	3420

tacctgtccc	tgacactgtc	cccatgctg	tccccactt	tcccagctt	tccctgtccc	3480
ccacgtgtg	cctacctgtc	cctgacactg	acccccatgc	tgcccgacc	tgccccccac	3540
tctccccacc	tctccctgtc	acccacgtg	tccctacctg	tccctgacac	tgccccccat	3600
gctgtcccca	cctgtccccc	aatctcccca	cctctccctg	tccccacgc	tgccccacc	3660
tgccctgac	gttgtcttct	gtgttatcca	catgctgtca	ctaccatggc	tctgctctcc	3720
atgtccaggc	ctgggggcag	gcagtgtaga	gccccggtac	ctgggtggcc	tgaaagacag	3780
atgggccttg	ggagcagggc	tgtggcctgg	gtggcctgag	gggtgggtgg	ggctcggggg	3840
cagggtgtg	gcctcgctca	cccctgtgct	gtgccttgcc	tacaggtgaa	gtggatcttc	3900
tcctcagtgg	tggacctgaa	gcagaccatc	gtccccgact	acaggaacat	gataaggcag	3960
ggggcctagg	gccaccctct	gcggggtgtc	cagggccgcc	cagacccac	acacgagccg	4020
tgggccatgc	tcagccacca	cccaggccac	acctgcccc	tgacctcacc	gccctcaacc	4080
ccatggctct	ctggcttcgc	agtcgcctc	tgagccctga	aacgcccccc	ttccagaccc	4140
tgtgcatagc	aggtctaccc	cagacctccg	ctgcttggtg	catgcagggc	gctggggggc	4200
aggtgtcccc	tcagcaggac	gtccctgccc	tctggaccac	caggtgctca	cacaaaagga	4260
ggtaaccggc	atcccaggcc	cccactcagg	caggacctcg	ccctggagcc	aactccgtcc	4320
acgccagcct	cctgaacaca	ggcatggttt	ccagatggtg	agtgggagca	tcagtcgcca	4380
aggtagggaa	gccacagcac	catcaggccc	tgttggggag	gcttccgaga	gctgcgaagg	4440
ctcactcaga	cggccttcct	cccagcccg	agccagacag	cctccattcc	gggcactccc	4500
gtgaactcct	gacatgagga	atgaggttgt	tctgatttca	agcaaagaac	gctgctctct	4560
ggctcctgag	aacagtcccg	gtgccagcac	cacccttggt	ctgtctgccc	acactgctgg	4620
attctcgggt	ggaactcgac	ccgcagggac	agccagcccc	agagtccgca	ctggggagag	4680
aaggggcccag	gcccaggaca	ctgccacctc	ccaccactc	cagtccaccg	agatcactca	4740
gagaagagcc	tgggccatgt	ggccgctgca	ggagccccac	agtgcaaggg	tgaggatagc	4800
ccaaggaagg	gctgggcatc	tgcccagaca	ggcctccac	agaaggctgg	tgaccaggtc	4860
ccaggcgggc	aagactcagc	cttggtgggg	cctgaggaca	gaggaggccc	aggagcatcg	4920
gggagagagg	tggagggaca	ccgggagagc	caggagcgtg	gacacagcca	gaactcatca	4980
cagaggctgg	cgtccagtcc	cgggtcacgt	gcagcaggaa	caagcagcca	ctctgggggc	5040
accaggtgga	gaggcaagac	gacaaagagg	gtgcccgtgt	tcttgcgaaa	gcggggctgc	5100
tggccacgag	tgctggacag	aggccccac	gctctgctgc	ccccatcacg	ccgttccgtg	5160
actgtcacgc	agaatccaca	gacaggaagg	gaggctcgag	cgggactgcg	gccagcgctt	5220
gcctcggccg	tcaggaggga	ctcctgggct	cactcgaagg	aggtgtcacc	atttcagctt	5280
tggcttttct	tcttctttta	aattttctaa	agctcattaa	ttgtctttga	tgtttctttt	5340

```

gtgatgacaa taaaatatcc tttttaagtc ttgtacttcg tgatgggagc cgccttcctg 5400
tgtccacgcg cctcctgccc ccggtgggaa gcacggtcag gaggaggctg gtccagctgc 5460
acctcgggggg ctccctgcac tcgccccccg cctcctgcag ccacacgcat tgcccagagc 5520
gccctccctg gccctgtcg ctacatggac ccctggggct tctcctcttt tctacatgga 5580
tgcagtttct cctcctgctg ggcacggtcg tgcccgccct ggtcactctg cgggggacag 5640
ggcctccagg gaaagctggg tcgaggctgg gagctggctc aggtggcca ggcagagcca 5700
cagggagggc cttccagaac caaccatggt gtgaagcgag aggtgggtgt cagatctgtg 5760
tgcgtcagct caggaccaca gcggggcagc tcccacggca gacatggatc cactagttct 5820
aga 5823

```

```

<210> 6
<211> 1380
<212> DNA
<213> Mus musculus

```

```

<220>
<221> CDS
<222> (1)..(1380)

```

```

<400> 6
atg aaa gtg ttg agt ctg ttg tac ctg ttg aca gcc att cct ggt atc 48
Met Lys Val Leu Ser Leu Leu Tyr Leu Leu Thr Ala Ile Pro Gly Ile
1 5 10 15

ctg tct gac gta cag ctt cag cag tca gga cct ggc ctg gtg aaa cct 96
Leu Ser Asp Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro
20 25 30

tct cag tct ctg tcc ctc acc tgc act gtc act ggc tac tca atc acc 144
Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr
35 40 45

agt gat tct gcc tgg aac tgg atc cgg cag ttt cca gga aac aga ctg 192
Ser Asp Ser Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Arg Leu
50 55 60

gag tgg atg ggc tac ata agc tac agt ggt agc act agc tac aac cca 240
Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro
65 70 75 80

tct ctc aaa agt cga atc tct atc act cga gac aca tcc aag aac cag 288
Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
85 90 95

ttc ttc ctg cag ttg aac tct gtg act act gag gac aca gcc aca tat 336
Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr
100 105 110

tac tgt gta aga ggg ctc cgg ttt gct tac tgg ggc caa ggg act ctg 384
Tyr Cys Val Arg Gly Leu Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu
115 120 125

gtc act gtg agc tca gct agc acc aag ggc cca tcc gtc ttc ccc ctg 432

```

Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	Val	Phe	Pro	Leu	
130						135					140					
gcg	ccc	tgc	tcc	agg	agc	acc	tcc	gag	agc	aca	gcc	gcc	ctg	ggc	tgc	480
Ala	Pro	Cys	Ser	Arg	Ser	Thr	Ser	Glu	Ser	Thr	Ala	Ala	Leu	Gly	Cys	
145					150					155					160	
ctg	gtc	aag	gac	tac	ttc	ccc	gaa	ccg	gtg	acg	gtg	tcg	tgg	aac	tca	528
Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	Ser	Trp	Asn	Ser	
				165					170					175		
ggc	gcc	ctg	acc	agc	ggc	gtg	cac	acc	ttc	ccg	gct	gtc	cta	cag	tcc	576
Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	Val	Leu	Gln	Ser	
			180					185					190			
tca	gga	ctc	tac	tcc	ctc	agc	agc	gtg	gtg	acc	gtg	ccc	tcc	agc	agc	624
Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	Pro	Ser	Ser	Ser	
		195					200					205				
ttg	ggc	acg	aag	acc	tac	acc	tgc	aac	gta	gat	cac	aag	ccc	agc	aac	672
Leu	Gly	Thr	Lys	Thr	Tyr	Thr	Cys	Asn	Val	Asp	His	Lys	Pro	Ser	Asn	
	210					215					220					
acc	aag	gtg	gac	aag	aga	gtt	gag	tcc	aaa	tat	ggt	ccc	cca	tgc	cca	720
Thr	Lys	Val	Asp	Lys	Arg	Val	Glu	Ser	Lys	Tyr	Gly	Pro	Pro	Cys	Pro	
225					230					235					240	
tca	tgc	cca	gca	cct	gag	ttc	ctg	ggg	gga	cca	tca	gtc	ttc	ctg	ttc	768
Ser	Cys	Pro	Ala	Pro	Glu	Phe	Leu	Gly	Gly	Pro	Ser	Val	Phe	Leu	Phe	
				245					250					255		
ccc	cca	aaa	ccc	aag	gac	act	ctc	atg	atc	tcc	cgg	acc	cct	gag	gtc	816
Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg	Thr	Pro	Glu	Val	
			260					265					270			
acg	tgc	gtg	gtg	gtg	gac	gtg	agc	cag	gaa	gac	ccc	gag	gtc	cag	ttc	864
Thr	Cys	Val	Val	Val	Asp	Val	Ser	Gln	Glu	Asp	Pro	Glu	Val	Gln	Phe	
		275					280					285				
aac	tgg	tac	gtg	gat	ggc	gtg	gag	gtg	cat	aat	gcc	aag	aca	aag	ccg	912
Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala	Lys	Thr	Lys	Pro	
	290					295					300					
cgg	gag	gag	cag	ttc	aac	agc	acg	tac	cgt	gtg	gtc	agc	gtc	ctc	acc	960
Arg	Glu	Glu	Gln	Phe	Asn	Ser	Thr	Tyr	Arg	Val	Val	Ser	Val	Leu	Thr	
305				310						315					320	
gtc	ctg	cac	cag	gac	tgg	ctg	aac	ggc	aag	gag	tac	aag	tgc	aag	gtc	1008
Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr	Lys	Cys	Lys	Val	
				325					330					335		
tcc	aac	aaa	ggc	ctc	ccg	tcc	tcc	atc	gag	aaa	acc	atc	tcc	aaa	gcc	1056
Ser	Asn	Lys	Gly	Leu	Pro	Ser	Ser	Ile	Glu	Lys	Thr	Ile	Ser	Lys	Ala	
			340					345					350			
aaa	ggg	cag	ccc	cga	gag	cca	cag	gtg	tac	acc	ctg	ccc	cca	tcc	cag	1104
Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu	Pro	Pro	Ser	Gln	
		355					360					365				
gag	gag	atg	acc	aag	aac	cag	gtc	agc	ctg	acc	tgc	ctg	gtc	aaa	ggc	1152
Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys	Leu	Val	Lys	Gly	
	370					375					380					

ttc tac ccc agc gac atc gcc gtg gag tgg gag agc aat ggg cag ccg 1200
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 385 390 395 400

gag aac aac tac aag acc acg cct ccc gtg ctg gac tcc gac ggc tcc 1248
 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 405 410 415

ttc ttc ctc tac agc agg cta acc gtg gac aag agc agg tgg cag gag 1296
 Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
 420 425 430

ggg aat gtc ttc tca tgc tcc gtg atg cat gag gct ctg cac aac cac 1344
 Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 435 440 445

tac aca cag aag agc ctc tcc ctg tct ctg ggt aaa 1380
 Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 450 455 460

<210> 7

<211> 460

<212> PRT

<213> Mus musculus

<400> 7

Met Lys Val Leu Ser Leu Leu Tyr Leu Leu Thr Ala Ile Pro Gly Ile
 1 5 10 15

Leu Ser Asp Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro
 20 25 30

Ser Gln Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr
 35 40 45

Ser Asp Ser Ala Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Arg Leu
 50 55 60

Glu Trp Met Gly Tyr Ile Ser Tyr Ser Gly Ser Thr Ser Tyr Asn Pro
 65 70 75 80

Ser Leu Lys Ser Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
 85 90 95

Phe Phe Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr
 100 105 110

Tyr Cys Val Arg Gly Leu Arg Phe Ala Tyr Trp Gly Gln Gly Thr Leu
 115 120 125

Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
 130 135 140

Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys
 145 150 155 160
 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
 165 170 175
 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
 180 185 190
 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
 195 200 205
 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn
 210 215 220
 Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro
 225 230 235 240
 Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe
 245 250 255
 Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val
 260 265 270
 Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe
 275 280 285
 Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro
 290 295 300
 Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr
 305 310 315 320
 Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val
 325 330 335
 Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala
 340 345 350
 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln
 355 360 365
 Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly
 370 375 380
 Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro
 385 390 395 400

Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser
 405 410 415

Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu
 420 425 430

Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His
 435 440 445

Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
 450 455 460

<210> 8

<211> 1054

<212> DNA

<213> Artificial

<220>

<223> synthetic nucleotide

<400> 8

```

aagcttaccg ccacatggag acagacacaa tcctgctatg ggtgctgctg ctctggggttc      60
caggctccac tggtgacatt gtacttacac agtctccagc ttctttggct gtgtctcttag      120
ggcagagggc caccatatcc tgcagagcca gtgaaagtgt tgatagttat gtcaatagtt      180
ttctccactg gtaccagcag aaaccaggac agccacccaa actcctcatc tatcgtgcat      240
ccaacctaca atctgggata cctgccaggt tcagtggcag tgggtctagg acagacttca      300
ccctcaccat taatcctgtg gaggtgatg atgttgcaac ctattactgt cagcaaagta      360
atgaggatcc gtacacgttc ggagggggga ccaagctgga aataaaacgg actgttgcg      420
cgccgtctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgcctctg      480
ttgtgtgcct gctgaataac ttctatccca gagaggccaa agtgacagtg aagggtggata      540
acgccctcca atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca      600
cctacagcct cagcagcacc ctgacgtga gcaaagcaga ctacgagaaa cacaaagtct      660
acgcctgcga agtcacccat cagggcctga gctcgcccg      cacaaagagc ttcaacaggg      720
gagagtgtta gagggagaag tgccccacc tgctcctcag ttccagcctg accccctccc      780
atcctttggc ctctgaccct tttccacag gggacctacc cctattgcgg tcctccagct      840
catctttcac ctcaccccc      tcctcctcct tggctttaat tatgctaata ttggaggaga      900
atgaataaat aaagtgaatc tttgcacctg tggtttctct ctttcctcat ttaataatta      960
ttatctgttg ttttaccaac tactcaattt ctcttataag ggactaaata tgtagtcac      1020
ctaaggcgca taaccggatc cactagttct agag      1054

```

<210> 9

<211> 714
 <212> DNA
 <213> mus musculus

<220>
 <221> CDS
 <222> (1)..(714)

<400> 9

atg gag aca gac aca atc ctg cta tgg gtg ctg ctg ctc tgg gtt cca	48
Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Leu Trp Val Pro	
1 5 10 15	
ggc tcc act ggt gac att gta ctt aca cag tct cca gct tct ttg gct	96
Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala	
20 25 30	
gtg tct cta ggg cag agg gcc acc ata tcc tgc aga gcc agt gaa agt	144
Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser	
35 40 45	
gtt gat agt tat gtc aat agt ttt ctc cac tgg tac cag cag aaa cca	192
Val Asp Ser Tyr Val Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro	
50 55 60	
gga cag cca ccc aaa ctc ctc atc tat cgt gca tcc aac cta caa tct	240
Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Gln Ser	
65 70 75 80	
ggg atc cct gcc agg ttc agt ggc agt ggg tct agg aca gac ttc acc	288
Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr	
85 90 95	
ctc acc att aat cct gtg gag gct gat gat gtt gca acc tat tac tgt	336
Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys	
100 105 110	
cag caa agt aat gag gat ccg tac acg ttc gga ggg ggg acc aag ctg	384
Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Thr Lys Leu	
115 120 125	
gaa ata aaa cgg act gtt gcg gcg ccg tct gtc ttc atc ttc ccg cca	432
Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro	
130 135 140	
tct gat gag cag ttg aaa tct gga act gcc tct gtt gtg tgc ctg ctg	480
Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu	
145 150 155 160	
aat aac ttc tat ccc aga gag gcc aaa gtg cag tgg aag gtg gat aac	528
Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn	
165 170 175	
gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca gag cag gac agc	576
Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser	
180 185 190	
aag gac agc acc tac agc ctc agc agc acc ctg acg ctg agc aaa gca	624
Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala	
195 200 205	
gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc acc cat cag ggc	672

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
 210 215 220

ctg agc tcg ccc gtc aca aag agc ttc aac agg gga gag tgt 714
 Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
 225 230 235

<210> 10
 <211> 238
 <212> PRT
 <213> mus musculus

<400> 10

Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Leu Trp Val Pro
 1 5 10 15

Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala
 20 25 30

Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Glu Ser
 35 40 45

Val Asp Ser Tyr Val Asn Ser Phe Leu His Trp Tyr Gln Gln Lys Pro
 50 55 60

Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser Asn Leu Gln Ser
 65 70 75 80

Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg Thr Asp Phe Thr
 85 90 95

Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala Thr Tyr Tyr Cys
 100 105 110

Gln Gln Ser Asn Glu Asp Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu
 115 120 125

Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro
 130 135 140

Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu
 145 150 155 160

Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
 165 170 175

Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser
 180 185 190

Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala
195 200 205

Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly
210 215 220

Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
225 230 235

INTERNATIONAL SEARCH REPORT

International application No

US2005/044735

A. CLASSIFICATION OF SUBJECT MATTER

C12P21/02 C07K16/00 C12N5/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12P C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NORDERHAUG LARS ET AL: "Balanced expression of single subunits in a multisubunit protein, achieved by cell fusion of individual transfectants." EUROPEAN JOURNAL OF BIOCHEMISTRY / FEBS. JUL 2002, vol. 269, no. 13, July 2002 (2002-07), pages 3205-3210, XP002374789 ISSN: 0014-2956 cited in the application the whole document	1-4, 9-11, 13-15
Y		5-8, 16-19
Y	US 2004/142430 A1 (HORI NOBUAKI ET AL) 22 July 2004 (2004-07-22) the whole document ----- -/--	5,16-19



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

29 March 2006

Date of mailing of the international search report

27/04/2006

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pérez-Mato, I

INTERNATIONAL SEARCH REPORT

ational application No
1/US2005/044735

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RUNNING DEER JENNIFER ET AL: "High-level expression of proteins in mammalian cells using transcription regulatory sequences from the Chinese hamster EF-1alpha gene." BIOTECHNOLOGY PROGRESS. 2004 MAY-JUN, vol. 20, no. 3, May 2004 (2004-05), pages 880-889, XP002374790 ISSN: 8756-7938 cited in the application page 887, column 1, line 11 - page 888, column 1, line 14 -----	6-8
Y	ZAHN-ZABAL M ET AL: "Development of stable cell lines for production or regulated expression using matrix attachment regions" JOURNAL OF BIOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 87, no. 1, 27 April 2001 (2001-04-27), pages 29-42, XP004231294 ISSN: 0168-1656 cited in the application page 34, column 2, line 11 - page 36, column 2, line 28 -----	6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

/US2005/044735

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2004142430 A1	22-07-2004	US 2003022291 A1	30-01-2003